Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial.

@article{Murphy2000ProspectiveCG,
  title={Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial.},
  author={Micheal E. P. Murphy and Martin Beaman and L. Scott Clark and Michelle Cayouette and Lacey Benson and Danielle M Morris and Joseph W. Polli},
  journal={Pharmacogenetics},
  year={2000},
  volume={10 7},
  pages={583-90}
}
A phase III study was performed to compare the efficacy and safety of lamotrigine (Lamictal), desipramine (Norpramin), and placebo in the treatment of unipolar depression. Desipramine is extensively metabolized by cytochrome P450 2D6 (CYP2D6), and kinetics of this compound are altered in poor metabolizers. Genotyping was utilized to exclude poor metabolizers in order to increase subject safety and to eliminate the need to continuously monitor plasma desipramine levels. As part of screening… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Development of neuroleptic agents: pharmacogenetics and current safety issues of regulatory concern

Dialogues in clinical neuroscience • 2002
View 4 Excerpts
Highly Influenced

Regulatory aspects of pharmacogenetics and pharmacogenomics

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz • 2003
View 1 Excerpt

Similar Papers

Loading similar papers…